Tagged with Novo Nordisk

Global As Big Pharma makes evermore declarations on its sustainability credentials, who are the industry’s most sustainable companies? With wildlife under severe threat from biopharmaceutical run-off, which companies are truly dedicated to change? Which are truly dedicated to equitable pay structures and promoting diversity, equity and inclusion? To answer these questions,…

India India faces a significant diabetes burden, with some observers even labelling the country ‘The Diabetes Capital of the World’. Around 101.4 million adults, or 11 percent of the Indian population, have diabetes.   As Dr Brij Mohan, president of India’s Diabetes & Obesity Centre surmises, Indians tend to develop diabetes…

India Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened up its clinical research regulations and saw a significant drop in trial numbers. However, with a revised regulatory landscape, a…

Portugal Diabetes is a rising threat to the Portuguese people, the country’s healthcare system, and its economy. Portugal’s National Diabetes Observatory observed that 1.1 million Portuguese people between the ages of 20 and 79.5 (out of a total population of just 10.3 million) were living with diabetes in 2021.   This…

Portugal Novo Nordisk’s spectacular ascendancy in 2023 has meant that its country managers across the world have had to embrace scrutiny and press coverage like never before.   In its centenary year, the Danish firm’s new generation of obesity drugs supercharged revenues to around EUR 30 billion, a 30 percent hike…

India Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation. Now though, as India’s GDP and market value soar and the policy environment shifts towards prioritising the domestic development of…

Portugal Paula Barriga, VP & GM at Novo Nordisk Portugal, discusses the high prevalence of obesity, which affects over two million people in a country where none of the available pharmacological obesity treatments are currently reimbursed and where access to innovation is slow by European standards. She explains the need for…

Europe Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to carve out a slice of this huge growth market. Those who made a bet on obesity years in advance are…

India Vikrant Shrotiya outlines how Novo Nordisk’s phenomenal recent global performance in obesity and diabetes has played out in India and the relevance of India to the global group. He also examines some of the key affordability and access challenges in the Indian market and how the company is engaging in…

Global Last year’s COP28 summit saw a host of pharma players touting their green credentials, as PharmaBoardroom’s Louis Haynes explores here. This is an extract from our Transformative 2023: Regional Pharma Trends report, available for free download now.   At the recent COP28 climate change conference in the UAE, industry bodies…

Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility.   Johnson & Johnson Innovation…

Global Ever since Novo Nordisk launched Wegovy two years ago, the company has struggled to meet the huge demand for its breakthrough weight loss drug and is yet to make it available in a larger range of markets. Following a recent launch in Germany, Novo Nordisk CEO Lars Fruergaard Jørgensen makes…